Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study.
about
Aldosterone antagonists for preventing the progression of chronic kidney diseaseDiuretics: a review and updateEplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4--a randomized controlled study.Mineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis.Myeloid mineralocorticoid receptor activation contributes to progressive kidney disease.Suppression of Rapidly Progressive Mouse Glomerulonephritis with the Non-Steroidal Mineralocorticoid Receptor Antagonist BR-4628.Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysisMineralocorticoid receptor antagonist for renal protection.Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy.Cardiovascular actions of mineralocorticoid receptor antagonists in patients with chronic kidney disease: A systematic review and meta-analysis of randomized trials.The Role of the Mineralocorticoid Receptor in Inflammation: Focus on Kidney and Vasculature.CS-3150, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, Shows Preventive and Therapeutic Effects On Renal Injury in Deoxycorticosterone Acetate/Salt-Induced Hypertensive Rats.Inhibition of local aldosterone by eplerenone reduces renal structural damage in a novel model of chronic cyclosporine A nephrotoxicity.The effect of spironolactone on calcineurin inhibitor induced nephrotoxicity: a multicenter randomized, double-blind, clinical trial (the SPIREN trial).
P2860
Q24194979-3C57044E-6A7F-4862-BC54-8E653F2D090CQ28302157-B923BB5E-7B1E-4101-9676-6343CDD43780Q31118126-CF161AF3-411C-412E-B6EE-4DB44F7933F5Q33734806-0B7FBAD6-6E49-4531-8A46-9369BF3734ACQ34259981-762AF19D-CF65-4010-BC5E-08E375DF25AEQ35877719-B9289CC0-7026-400B-90B7-93A041A795EAQ36127484-996D454F-A3BE-4506-AD09-162B4746C047Q37998573-0B3F6D6D-511B-4282-9FB1-415AB90B7A63Q38052452-8136871B-6D97-4AB0-9CC9-EC206E880252Q38382456-FD4D3358-FC5F-4119-A9A7-4CE80655AB28Q48025446-2FD09D6B-1E43-483A-A345-5D6D6ADF16C1Q51659952-FABC4FC8-2AC5-45BB-BBBF-D1EF2D016985Q53670434-DFC3FD8B-78E6-4135-B3C1-EC4353463441Q55280810-51E73472-640E-457D-A54D-B24E289094CB
P2860
Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study.
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Moderate antiproteinuric effec ...... A randomized cross-over study.
@ast
Moderate antiproteinuric effec ...... A randomized cross-over study.
@en
Moderate antiproteinuric effec ...... A randomized cross-over study.
@nl
type
label
Moderate antiproteinuric effec ...... A randomized cross-over study.
@ast
Moderate antiproteinuric effec ...... A randomized cross-over study.
@en
Moderate antiproteinuric effec ...... A randomized cross-over study.
@nl
prefLabel
Moderate antiproteinuric effec ...... A randomized cross-over study.
@ast
Moderate antiproteinuric effec ...... A randomized cross-over study.
@en
Moderate antiproteinuric effec ...... A randomized cross-over study.
@nl
P2093
P2860
P1433
P1476
Moderate antiproteinuric effec ...... A randomized cross-over study.
@en
P2093
Anne-Lise Kamper
Lene Boesby
Thomas Elung-Jensen
Tobias Wirenfeldt Klausen
P2860
P304
P356
10.1371/JOURNAL.PONE.0026904
P407
P577
2011-11-04T00:00:00Z